Neuroscios and Data Magik Strong partners in Neuroscience

The ideal combination of expertise in the field of neurodegenerative disorders.

NeuroScios and Data Magik started their partnership already more than 10 years ago. Whilst NeuroScios combines knowledge in preclinical and clinical CNS drug development, Data Magik provides matching experience in specific data capture tools and statistical methods.

  • Collaboration on multiple projects

  • The companies are acting as one team

  • Seamless integration of experience

  • Innovative concepts /


Phase I Clinical Trials  are the fundament of a clinical drug development program.

25% of our clinical trials were Phase I trials. Since more than 30 years we design drug development programs  exactly to the needs of our clients. Our services include strategic considerations, medical  writing, statistical planning, study conduct, project management, monitoring and more. Our large scientific network of connects you with opinion leaders, investigators and international experts  with a special focus on neurodegenerative diseases or other indications as needed. Throughout Central and Eastern European Countries our investigator network provides you access to your targeted patient population or special population groups. In addition we offer access to Phase I units which are able to meet your requirements. The Neuroscios specialists are familiar with regulatory procedures in Central and Eastern European Countries.

As safety is the primary endpoint of a Phase I clinical trial you would like to have the strong pharmacovigilance team of NeuroScios. In addition Neuroscios is able to set up a Data and Safety Monitoring Board (DSMB) to ensure periodic medical review and ensure subject safety - and guarantees you the opinion of true experts.

Neuroscios has over 30 years of experience in drug development and 15 years of experience in the conduct of clinical trials with a strong focus on neurodegenerative diseases. This experience might make the difference between success and failure of your clinical trial.